Hans Hammers, MD, PhD

Hans Hammers, MD, PhD, Department of Internal Medicine, UT Southwestern Medical Center

Articles by Hans Hammers, MD, PhD

Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
View More
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel highlighted the CheckMate 9ER study and implications for clinical practice.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for their practice.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel considered the role of SBRT as well as MDT in RCC. They also weighed in on variant histology considerations.
Rana McKay, MDRenal Cell Carcinoma | February 8, 2024
The panel weigh the treatment considerations of IO/IO versus IO/TKI for advanced renal cell carcinoma.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel discusses excitement for the future in kidney cancer: CAR-T, adjuvant checkpoint inhibitors, and sequencing.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel shared thoughts on the TIDE-A study and best practices for starting and stopping TKI therapy in RCC patients
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel discussed the results of the LITESPARK-005 trial, as well as the role of biomarkers in kidney cancer.
Brian Rini, MD, FASCORoundtable | December 8, 2023
The panel talks about non-clear cell kidney cancer, including treatment options and clinical trial data in this subgroup.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel addresses the place for immune monotherapy, as well as takeaways from trials like PDIGREE, PROBE, and more.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel reacts to the RENOTORCH study presented at ESMO and compares the frontline doublet treatment options for RCC.
Brian Rini, MD, FASCORoundtable | November 16, 2023
The panel shared their approach to treatment selection for clear cell kidney cancer.
Hans Hammers, MD, PhDRenal Cell Carcinoma | September 8, 2023
Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.